Simulations Plus to Attend Investor Conferences in Boston and New York City
ByAinvest
Wednesday, Aug 27, 2025 6:15 pm ET1min read
SLP--
Simulations Plus provides advanced software and consulting services to the biopharma industry, focusing on drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company's solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Their technology is utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide [1].
The participation of O'Connor in these high-profile conferences provides an opportunity for investors to gain insights into Simulations Plus's strategies, market position, and future prospects. Interested parties can access the webcast links on the scheduled dates and times to follow these events.
References:
[1] https://www.stocktitan.net/news/SLP/simulations-plus-to-participate-in-upcoming-investor-uom4jckq1imi.html
[2] https://www.stocktitan.net/news/LLY/lilly-to-participate-in-morgan-stanley-23rd-annual-global-healthcare-ngk18zw3oh9e.html
Simulations Plus CEO Shawn O'Connor will attend the 2025 Wells Fargo Healthcare Conference in Boston and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City. The events will feature fireside chats and one-on-one meetings, and interested parties can access webcast links on the scheduled dates and times. Simulations Plus provides cheminformatics, biosimulation, and simulation-enabled performance solutions to the biopharma industry, integrating AI/ML technologies and various modeling approaches.
Simulations Plus, Inc. (SLP) has announced that Shawn O'Connor, Chief Executive Officer, will participate in two significant investor events in September. The first event is the 2025 Wells Fargo Healthcare Conference in Boston, where O'Connor will engage in a fireside chat and one-on-one meetings on Wednesday and Thursday, September 3-4, 2025. The webcast link for the event is available here [1]. The second event is the Morgan Stanley 23rd Annual Global Healthcare Conference in New York City, scheduled for Wednesday, September 10, 2025. O'Connor will also participate in a fireside chat and one-on-one meetings at this event. The webcast link for this event can be found here [2].Simulations Plus provides advanced software and consulting services to the biopharma industry, focusing on drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The company's solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Their technology is utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide [1].
The participation of O'Connor in these high-profile conferences provides an opportunity for investors to gain insights into Simulations Plus's strategies, market position, and future prospects. Interested parties can access the webcast links on the scheduled dates and times to follow these events.
References:
[1] https://www.stocktitan.net/news/SLP/simulations-plus-to-participate-in-upcoming-investor-uom4jckq1imi.html
[2] https://www.stocktitan.net/news/LLY/lilly-to-participate-in-morgan-stanley-23rd-annual-global-healthcare-ngk18zw3oh9e.html

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet